- Country: Germany
- Summary: Open House Drug Rebate Agreements Everolimus, Atc L04aa18 and Everolimus as Off-Patent Oncology Indications not Related to Tuberous Sclerosis (Tsc), Atc L01eg02
- DET Ref No: 77508900
- Deadline: 05 Jan 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: EUR 1.00
- Notice Type: Tender
- Document Ref. No.: 035151-2023
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- See Procurement Description
Doc Title: Pharmaceutical products
Contract Type: Supplies - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINOpen House Drug Rebate Agreements Everolimus, Atc L04aa18 and Everolimus as Off-Patent Oncology Indications not Related to Tuberous Sclerosis (Tsc), Atc L01eg02 - Germany Tender
The AOK BAVARIA - THE HEALTH INSURANCE COMPANY, a Government sector organization in Germany, has announced a new tender for Open House Drug Rebate Agreements Everolimus, Atc L04aa18 and Everolimus as Off-Patent Oncology Indications not Related to Tuberous Sclerosis (Tsc), Atc L01eg02. This tender is published on GermanyTenders under DET Ref No: 77508900 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-01-05.
The estimated tender value is EUR 1.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
